sur NanoViricides, Inc. (NASDAQ:NNVC)
NV-387: A Prospective Antiviral for Pediatric Use by NanoViricides
NanoViricides, Inc., a clinical-stage company, has announced positive safety results for its broad-spectrum antiviral NV-387 in a juvenile mouse study. This study is a potential breakthrough, paving the way for pediatric clinical trials targeting serious viral infections like Ebola, Mpox, and Measles, which lack effective treatments.
NV-387 is currently involved in Phase II clinical trials for Ebola and Mpox in the Democratic Republic of Congo. Children, often disproportionally affected by these viruses, could benefit significantly if Phase III trials confirm efficacy. Moreover, NV-387 has received Orphan Drug Designation for Measles, indicating FDA interest due to its unmet medical need status.
The juvenile mouse study highlights NV-387's strong safety profile, with no observed adverse effects at high dosage levels. NanoViricides anticipates expanding its clinical trials to include pediatric cohorts, marking a significant step towards addressing global viral disease challenges in younger populations.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NanoViricides, Inc.